TP53 and small cell lung carcinoma: In 2015, comprehensive genomic profiles of SCLC have been performed detecting, besides p53/RB1 loss, rare kinase gene mutations (potentially targets for new drugs) and inactivating mutations in NOTCH family genes in around 25% of SCLC [71].